Merck to Present New Data on VICTRELIS® (boceprevir) and Investigational Compounds MK-5172 and Vaniprevir for Chronic Hepatitis C Virus at The International Liver CongressTM / 2013 EASL Annual Meeting
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--
Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
announced today that two analyses of VICTRELIS (boceprevir) and data
from Phase II studies of two of Merck’s investigational medicines for
chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir
(MK-7009), will be presented at the 2013 International Liver Congress
(EASL) Annual Meeting. The meeting will take place in Amsterdam from
April 24-28, 2013.
Language:
English
Contact HTML:
MerckMedia:Caroline Lappetito, 267-305-7369Sarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Authors: hq_site_admin Tags: Prescription Medicine News Corporate News Source Type: news
More News: Drugs & Pharmacology | Hepatitis | Hepatitis C | Liver | Merck | Politics | Study | Urology & Nephrology